TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Urinary excretion of uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Renal clearance of uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Fractional excretion of uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Subjective Ratings on Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Vision Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Visual Acuity On High Illumination High Contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of complete molecular response (CMR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Experiencing a High Risk Event
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Complete Response at 24 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Treatment Discontinuation Within the First 24 Weeks
Endpoint domain: Adverse events/effects
Primary endpoint: days in hospital after transfer from the ICU to a general ward
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Conformability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Condition of the Skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Activity Profile
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Bacterial diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of participants with undetectable HCV RNA at 12 weeks post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: neuroendocrine measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Disease activity score (DAS 28)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain sensitivity (Pressure Pain Detection Threshold, PPDT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective pain perception (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pramlintide pharmacokinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of stay on referring hospitalist's service
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change from Baseline in mean morning peak expiratory flow (PEF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Early detection of kidney affection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change of pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Number of New T1 Gadolinium-Enhancing Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: False negative rate (FNR)
Endpoint domain: Adverse events/effects
Primary endpoint: Olerud-Molander Outcome Score (OMAS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Comprehension of words and phrases
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean STA-PSV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uptake of iodine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Information satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: blood pressures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Radiologist's Lesion Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Steady State Plasma Concentrations of Doravirine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IOP from baseline to 1 month post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Total Endoscopic Nasal Polyps Score at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Nasal Obstruction Visual Analog Scale (VAS) Score During the 4 Weeks Prior to Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Weekly Parenteral Support Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the serum concentration-time curve (AUC0 t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faecal Calprotectin (FCP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prolonged abstinence from all tobacco
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Concentration of Midazolam Alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Total Plasma Concentration of Midazolam Alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Exposure of Midazolam Alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limbal Hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bulbar Hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BAROS Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cmax of single ascending doses of rh-Tβ4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in middle cerebral artery flow patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in regional cerebral oxygen saturation measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety symptom burden
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Biomarkers in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in PANSS Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid Use During Hospital Stay
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: graded baseline renin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Average weekly bowel movement frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of HIV-1 Infection
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Observed Serum Concentration (Cmax) for CAT-354
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration Time Curve (AUC[0 - t]) for CAT-354
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Elimination Phase Half-Life (t[1/2]el) for CAT-354
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Change From Baseline in Best Corrected Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tests of educational achievement and concentration
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: gains in weight and height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMI percentile for age and sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biomarkers e.g, glucose, insulin, lipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: brain hypoxia rate by NIRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: tissue hypoxia by HIF1a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue hypoxia by concentration of TAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue hypoxia by concentration of TOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Temperature change in ipsilateral arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nerve origin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Access to follow-up care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Staging of liver fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Expression level of semaphorin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composition of immunity cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antisocial behavior assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical Hyperalgesia Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle Osteoarthritis Score (AOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Clitoral Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Safety indexes of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity indexes of GMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunogenicity indexes of neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood dosage of hydroxychloroquine (HCQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Knowledge about anaesthesiology and role of anaesthetist
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Accelerometer-assessed physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in self-reported VAS pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reproducibility of electroencephalographic signals interpretation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Successful placenta extraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Volume of the PEI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attentional processes improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Postprocedural cardiac troponin release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HIV testing coupon redemption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from Baseline 'de Morton Mobility Index (DEMMI)'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline 'Functional Status Score for the ICU (FSS-ICU)'
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (composite of death due to liver failure, gastrointestinal bleeding, spontaneous bacterial peritonitis, need for liver transplant)
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of recurrence free survival
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of urinary tract infection (UTI)
Endpoint domain: Adverse events/effects
Primary endpoint: Findings from physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal lab results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression pattern of PCD regulatory genes bcl-2, bax, and bcl-xL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Induction of PCD by antisense oligonucleotides and/or tamoxifen citrate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Amount of Streptococcus mutans (measured in Colony Forming Units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline GAD7 Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Complete Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-free Survival at 18 Months
Endpoint domain: Mortality/survival
Primary endpoint: Sacral Region Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: The duration of oral mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With New or Progressive Multiple Organ Dysfunction Syndrome (NPMODS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorptive Clearance Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucociliary Clearance Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With 1-year Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of total sleep time spent in REM
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Detection of heterotopic gastric mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent change in Low Density Lipoprotein Cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Glaucoma Symptom Scale (GSS)-SYMP-6 Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Point-prevalence Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug trough levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: alcohol related consequences
Endpoint domain: Adverse events/effects
Primary endpoint: Gut Microflora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Peristalsis intestine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in seated blood pressure from baseline to 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in 24-hour ambulatory blood pressure from baseline to 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline Ovulatory Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: number of heart-failure related pharmaceutical interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Subjects With SAEs, AEs Leading to Withdrawal From the Study, NOCDs, AESIs and Medically Attended AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Subjects Achieving Seroconversion for Homologous Influenza Strains (Day 22)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects Achieving HI Titer ≥ 1:40 for Homologous Influenza Strains (Day 22)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Discomfort during the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Response as Assessed by >20% Change From Baseline in the Jaw Functional Limitation Scale (JFLS) Global Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of COVID-19 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power generated at FatMax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power generated at ventilatory threshold 1 (VT1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Power generated at ventilatory threshold 2 (VT2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-year CVD risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: spasticity-torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spasticity-modified Ashworth scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spasticity-homosynaptic post-activation depression (HPAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor neuron activity-Hmax / Mmax ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Refraction status (spherical equivalent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With Treatment Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of AGO178
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Curve (AUC) of AGO178
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: severe (grade III/IV) GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Acute grade 3 or higher gastrointestinal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Calibre & Density of Hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: high-resolution DTI of cervical spinal cord
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in electroencephalogram (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Offspring body fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: best achievable overall response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Valgus Degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic Valgus Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preschool Language Scale IV (PLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peabody Picture Vocabulary Test (PPVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Language ENvironment Analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma chromogranin A (CgA) concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Serum gastrin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: % variation in expired CO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Metastatic Disease in Internal Mammary Sentinel Lymph Nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Patients With Identifiable Internal Mammary Sentinel Lymph Nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean intraocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation of target sites on functional MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cycloplegic axial length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression Subscale of HADS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Fugl-Meyer Assessment of Motor Recovery for Upper Limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cephalic or breech presentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Changes of finishing files
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of sepsis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: CD-related Hospitalization, Surgery, ER Visits and Steroid Prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hypercalcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Nephrolithiasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Utilization of HIV Testing
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rescue analgesic consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention